Platelet-rich plasma protects tenocytes from adverse side effects of dexamethasone and ciprofloxacin

Show simple item record

dc.contributor.author Zargar Baboldashti, N en
dc.contributor.author Poulsen, Raewyn en
dc.contributor.author Franklin, SL en
dc.contributor.author Thompson, MS en
dc.contributor.author Hulley, PA en
dc.date.accessioned 2016-07-22T00:44:04Z en
dc.date.issued 2011-09-02 en
dc.identifier.citation American Journal of Sports Medicine, 2011, 39 (9), pp. 1929 - 1935 (7) en
dc.identifier.issn 0363-5465 en
dc.identifier.uri http://hdl.handle.net/2292/29544 en
dc.description.abstract BACKGROUND: Ruptured tendons heal very slowly and complete recovery from injury is uncertain. Platelet-rich plasma (PRP), a rich source of growth factors, is currently being widely tested as a soft tissue healing agent and may accelerate tendon repair. The authors assessed the ability of PRP to prevent in vitro adverse effects of 2 drugs commonly linked to tendon rupture and tendinopathy, glucocorticoids and fluoroquinolone antibiotics. HYPOTHESIS: The pro-healing response induced by PRP protects human tenocytes against the cytotoxic effects of dexamethasone and ciprofloxacin. STUDY DESIGN: Controlled laboratory study. METHODS: Human primary hamstring tenocytes were exposed to different doses of ciprofloxacin and dexamethasone with and without PRP. AlamarBlue, β-galactosidase assay, and live/dead stain were used to measure, respectively, viability, senescence, and death in tenocyte culture. RESULTS: The viability of cells exposed to high doses of ciprofloxacin was significantly decreased compared with controls, with no induced senescence but increased cell death. Dexamethasone reduced viable cell number without inducing overt cell death, but the number of senescent cells increased considerably. After co-treatment with 10% PRP, viable cell number increased significantly in both conditions and the number of dead cells decreased in ciprofloxacin-treated cultures. Moreover, dexamethasone-induced senescence was markedly reduced by co-treatment with 10% PRP. CONCLUSION: This study demonstrates that ciprofloxacin and dexamethasone have differing adverse effects on human tenocytes, with ciprofloxacin inducing cell death while dexamethasone primarily induces senescence. The authors showed that PRP can protect cultured human tenocytes against cell death or senescence induced by these drugs. CLINICAL RELEVANCE: Both ciprofloxacin and dexamethasone are highly effective in treatment of inflammatory and infectious conditions, therefore new strategies to minimize their adverse effects are of strong interest. These findings suggest the potential for local administration of PRP to enhance tendon healing in patients undergoing glucocorticoid or fluoroquinolone treatment. en
dc.description.uri http://www.ncbi.nlm.nih.gov/pubmed/21632978 en
dc.format.medium Print-Electronic en
dc.language English en
dc.publisher SAGE Publications (UK and US): No SAGE Choice en
dc.relation.ispartofseries American Journal of Sports Medicine en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0363-5465/ https://au.sagepub.com/en-gb/oce/the-green-route-%E2%80%93-open-access-archiving-policy en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.subject Tendons en
dc.subject Cells, Cultured en
dc.subject Humans en
dc.subject Rupture en
dc.subject Tendon Injuries en
dc.subject Ciprofloxacin en
dc.subject Dexamethasone en
dc.subject Glucocorticoids en
dc.subject Anti-Infective Agents en
dc.subject Platelet Transfusion en
dc.subject Wound Healing en
dc.subject Cell Aging en
dc.subject Cell Proliferation en
dc.subject Adult en
dc.subject Middle Aged en
dc.subject Tendinopathy en
dc.subject Platelet-Rich Plasma en
dc.subject Young Adult en
dc.title Platelet-rich plasma protects tenocytes from adverse side effects of dexamethasone and ciprofloxacin en
dc.type Journal Article en
dc.identifier.doi 10.1177/0363546511407283 en
pubs.issue 9 en
pubs.begin-page 1929 en
pubs.volume 39 en
dc.description.version VoR - Version of Record en
dc.rights.holder en
dc.identifier.pmid 21632978 en
pubs.author-url http://ajs.sagepub.com/content/39/9/1929 en
pubs.end-page 1935 en
pubs.publication-status Published en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Article en
pubs.elements-id 496437 en
pubs.org-id Medical and Health Sciences en
pubs.org-id School of Medicine en
pubs.org-id Medicine Department en
dc.identifier.eissn 1552-3365 en
pubs.record-created-at-source-date 2016-07-22 en
pubs.online-publication-date 2011-06-01 en
pubs.dimensions-id 21632978 en


Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics